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ABSTRACT
Enterovirus A71 (EV-A71) infections are one of the main etiological agents of hand, foot 
and mouth disease (HFMD) and herpangina worldwide. EV-A71 infection is a life-threatening 
communicable disease and there is an urgent global need for the development of vaccines for 
its prevention and control. The morbidity rate of EV-A71 infection differs between countries. 
The pathogen’s genetic lineages are undergoing rapid evolutionary changes. An association 
between the occurrence of EV-A71 infection and the circulation of different genetic strains of 
EV-A71 virus has been identified around the world. In this review, we present and discuss the 
molecular epidemiology and pathogenesis of the human disease caused by EV-A71 infection, 
as well as current prospects for the development of an EV-A71 vaccine.
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INTRODUCTION
Enterovirus A71 (EV-A71) is an important cause of hand, foot and mouth disease 
(HFMD) and herpangina1. EV-A71 infects infants and young children and most 
cases of infection (>70%) are symptomatic2,3. The predominant clinical presentation 
of HFMD is characterized by a febrile illness accompanied by a maculopapular 
rash or blisters on the hands, soles of feet and buttocks1,2. It is usually a self-
limiting infection, but it is highly contagious through fecal-oral transmission of 
oropharyngeal secretions2. The most common involved area in severe or fatal cases 
of EV-A71 is the brain stem2,3. 
EV-A71 is an RNA virus that belongs to the human enterovirus A (EV-A) species, 
genus Enterovirus, family Picornaviridae1. Viral particles have an icosahedral shape, 
are not enveloped and contain a single-strand, positive-sense RNA genome. The 
most common method for enterovirus genotyping targets the 1D gene encoding the 
VP1 capsid protein containing the major neutralizing epitopes4. Human-infecting 
enteroviruses species include enterovirus A (EV-A), EV-B, EV-C, and EV-D. The 
classification of human enteroviruses is based on each strain’s homology within 
the RNA region coding for the VP1 capsid protein1. 
Although the EV-A71 virus has been isolated in many countries, epidemics of EV-
A71 infection are predominantly found in the Asia-Pacific region2,3,5-9. The morbidity 
associated with EV-A71 infection varies from country to country1. Seasonal epidemic 
patterns of EV-A71 infection have been observed in several countries. In Asia, a 
higher incidence has been observed during the summer months10-12. Several studies 
have also shown variations in the peak season between different years13,14. Most cases 
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of EV-A71 infection occur in children five years of age and 
younger, and boys have a higher risk of EV-A71 infection 
than girls2,5. Because the virus has the potential to cause 
high morbidity and mortality among children, it is critical 
to understand the mechanisms of and control measures for 
EV-A71 infections. In this review, we present and discuss 
the molecular epidemiology and pathogenesis of EV-A71 
infections, as well the prospects for the development of an 
EV-A71 vaccine.
Data sources
All manuscripts used in this review were published 
between January 1965 and December 2017; these 
reports related to EV-A71 infections were extracted 
by searching Medline (National Library of Medicine, 
Bethesda, Maryland, USA) and PubMed using the phrases 
“enterovirus-A71” and “molecular epidemiology” or the 
key words “pathogenesis” or “vaccine.” The results were 
limited to manuscripts available in English. 
Molecular epidemiology
In 1969, EV-A71 was first isolated from a child with 
encephalitis in the USA14. Subsequently, several EV-A71 
epidemics were reported in the 1970s around the world, 
including the Americas, Europe, Australia and Asia15-31. 
The EV-A71 virus is enclosed by the capsid proteins 
VP1, VP2, VP3, and VP41. VP1 shows the major antigenicity 
and has been defined as the neutralization determinant1. 
Based on VP1 nucleotide sequence analysis, EV-A71 can 
be divided into three distinct genogroups (e.g., A, B, and 
C)1,25. Genogroup A includes the prototype EV-A71 strain 
(BrCr-CA-70); this strain was first isolated in 1969 in the 
USA14, although it was not identified until 2008, in China9. 
Genogroup B can be divided into subgenogroups B1-B5, 
and genogroup C can be further divided into subgenogroups 
C1-C516. Recently, the C4 genogroup was once more 
subdivided into the C4a and C4b lineages. Genogroup D 
was initially identified in India4, and genogroups E and F 
were initially identified in Africa4.
Table 1 shows the phylogenetic origins of the EV-A71 
strains that have been recently circulating in the Asia-Pacific 
region2,5,8,9,15-20. Genogroup A was not identified in the Asia-
Pacific region until 20089. In contrast, genogroups B and C 
have been responsible for several large-scale outbreaks in 
the Asia region since 199716. Four distinct subgenogroups 
(B3, B4, C1 and C2) were found to have been cocirculating 
in the Asia-Pacific region from 1990-2016. Subgenogroup 
C4, particularly the C4a lineage, has also emerged in the 
Asia-Pacific region. The evolutionary branch C4a has 
crucial nucleotides and amino acid mutations relative to 
the branch C4b, and these changes may be the primary 
reason for its increased neurovirulence, causing outbreaks 
in China18,19. Through genetic and antigenic analysis, 
EV-A71 subgenogroup C4a has been confirmed to have 
spread from China to Vietnam; a subsequent large-scale 
outbreak occurred in Ho Chi Minh City and Southern 
Vietnam in 201120. 
The phylogenetic origins of EV-A71 strains 
circulating outside the Asia-Pacific region are presented 
in Table 221-31. From 1963 to 1986, strains of EV-A71 
belonging to subgenogoup B0, B1 and B2 were isolated 
in the Netherlands27. In contrast, after 1987, genogroup 
B was replaced by genogroup C, lineages C1 and C223-30. 
The emergence of C2 was associated with a peak in 
hospitalizations in 2007. According to an epidemiological 
study, the EV-A71 subgenogroups B1, B2, C1 and C2 
circulated simultaneously in Europe, Australia and the 
USA21-29. B3-B5, C4and C5, which have caused large 
Table 1 - A summary of human enterovirus A71 genotypes circulating in Asia-Pacific countries, 1960-20162-9,15-20.
Countries
Years
1960-1969 1970-1979 1980-1989 1990-1999 2000-2009 2010-2016
Singapore -- -- -- B3, B4 B4, B5, C1 --
Malaysia -- -- -- B3, B4 B4, B5, C1, --
Australia -- -- -- B3, C2 C1 --
Japan -- -- -- B3, B4, C2 B4, B5, C2, C4a C2
Korea -- -- -- B4, C2 C2, C3, C4a, C4b C4a
Taiwan -- -- -- B4, C2 B4, B5, C4, C5 B5, C4
China -- -- -- -- C4 C4, C4a
Cambodia -- -- -- -- -- C4
Viet Nam -- -- -- -- -- C4, B5
-- indicates no data available. 
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epidemics in the Asia-Pacific region since 1997, have not 
been observed outside the Asia-Pacific region (Table 2).
Comparing the epidemics that have occurred over the 
past four decades, the epidemiologic features of EV-A71 
infections appear to be changing. EV-A71 infection 
has emerged as an important public health problem 
around the world. No association has been established 
between genotype and disease severity32. From 1900 to 
2016, infections were successively caused by viruses 
of subgenogroup B0, B1and B2, followed by a shift in 
this predominance to those belonging to subgenogroups 
C1, C2, C3, C4a and C4b. A molecular epidemiological 
study suggested that the evolution of the EV-A71 virus 
has global characteristics. Global herd immunity against 
C1 and C2 viruses could possibly explain why epidemics 
caused by subgenogroups B4 and C4 are restricted to the 
Asia-Pacific region27. Subgenogroup B5 has been reported 
to be antigenically distinct from B1, B4, C2 and C417 and 
could therefore pose a potential risk for epidemic spread 
outside the Asia region. 
Pathogenesis 
The clinical spectrum of EV-A71 infection presentations 
is quite wide, including skin eruptions, internal organs and 
neurological manifestations and even death1,2. 
EV-A71 is a highly neurotropic virus33. The most 
common internal organ involved in EV-A71 infections is 
the brain stem33. According to data derived from a study 
developed in mice, the strong neurotropism of EV-A71 and 
its retrograde axonal transport in neurons could underlie 
its major transmission route34. In previous studies34,35 in 
which mice were infected via oral and parenteral routes 
with a murine-adapted virus strain that originated from a 
fatal human case, the EV-A71 virus entered the CNS via 
peripheral motor nerves after skeletal muscle infection 
and continued to spread within the CNS through motor 
and other neuronal pathways. Inflammation was the 
most profound in the spinal cord gray matter, brainstem, 
hypothalamus, subthalamic and dentate nuclei in autopsy 
samples investigated in Malaysia35. Previous studies36,37 
have found that the EV-A71 virus mechanism of infection 
is primarily focused on the respiratory tract epithelium, 
from which it is subsequently able to enter a pre-existing 
population of dendritic cells at the infection site; these 
cells could potentially transmit the virus from local sites 
to other organs through the blood stream during the 
infectious process. 
In a previous study38, a total of 46 children with 
EV-A71-related brainstem encephalitis (EBE) were enrolled 
and subsequently underwent 1.5 Tesla magnetic resonance 
(MR) examinations of the brain. Among these 46 children, 
35 had MR images evidencing dorsal medulla oblongata 
involvement, 32 had evidence of pons involvement, 10 had 
evidence of midbrain involvement and 7 had evidence of 
dentate nucleus involvement. Patients with dorsal medulla 
oblongata involvement or multiple areas involvement were 
significantly more likely to have poorer outcomes than 
patients without these features.
Additional noteworthy findings include clinical 
manifestations of viremia. Viremia reportedly occurs more 
frequently in children one year of age or younger17,39. 
Most patients with viremia do not show severe clinical 
manifestations of EV-A71 infection. In addition, the 
occurrence of CNS involvement is not reportedly different 
between patients with and without viremia39.
Table 2 - A summary of human enterovirus A71 genotypes circulating in countries outside the Asia-Pacific region, 1960-201621-31. 
Countries
Years
1960-1969 1970-1979 1980-1989 1990-1999 2000-2009 2010-2016
France -- -- -- -- C1, C2, C4 C4
UK -- -- -- C1 C1, C2 --
Germany -- -- -- -- C1, C2 --
Austria -- -- -- -- C1, C4 -
Norway -- -- -- -- C1 --
Netherlands B0 B1 B2 C1 C1, C2 --
Hungary -- B1 -- -- C1, C4 --
Bulgaria -- B1 -- -- -- --
USA A B1 B2 C1, C2 C2 --
Canada -- -- -- -- -- --
Peru -- -- -- -- C1 --
-- indicates no data available. 
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What might cause severe or fatal clinical presentations 
of EV-A71 infection? Based on the results of one autopsy, 
EV-A71 infection can lead to severe or fatal disease due 
to pulmonary edema. The mechanism of pulmonary 
edema among patients with severe EV-A71 infection is 
currently unclear. Evidences40 suggest that the brainstem 
involvement characteristic of EV-A71 infection may be an 
important etiological mechanism of neurogenic pulmonary 
edema. Virus-host interactions significantly influence viral 
replication, virulence and pathogenicity during the viral life 
cycle41. However, tissue-specific virulence is still not well 
understood in both, cell-based assays and animal models, 
therefore further studies are needed. 
Vaccine development
Close person-to-person contact is considered the most 
common route of EV-A71 transmission. In areas where 
EV-A71 circulation is present, especially because the 
clinical manifestations of the majority of EV-A71 infections 
are mild or asymptomatic, public health interventions, 
such as the promotion of hand washing, are necessary for 
the effective prevention of EV-A71 infection. Because 
effective treatment may not always be available, the best 
way to control and eradicate EV-A71 infection is to develop 
an effective vaccine. Several EV-A71 vaccines have been 
produced1, including a subunit vaccine, a virus-like particle 
vaccine, DNA vaccines, a live-attenuated vaccine and an 
inactivated virus vaccine. The potential vaccines targeting 
EV-A71 are discussed in greater detail below. 
Subunit vaccine 
Currently, there are no effective antiviral drugs or 
vaccines for prevention of EV-A71 infection. A previous 
study has suggested the potential of the VP1 protein 
as a candidate antigen for an EV-A71 vaccine42,43. A 
recombinant VP1 protein of the EV-A71 virus has been 
produced in Escherichia coli, yeast and the baculovirus 
system42-44. Vaccination with a VP1 protein vaccine 
can induce neutralizing antibodies to protect against 
EV-A71 infection42-44. However, another study showed 
that vaccination with a recombinant VP1 induced a lower 
titer of EV-A71-specific IgG antibodies than inoculation 
with the inactivated virus42,43. Although recombinant VP1 
vaccine can elicit similar levels of neutralizing antibodies, 
it provided effective protection only at a low challenge 
dose of EV-A7142. 
In another study45, antiserum was produced in mice 
against overlapping synthetic peptides elicited by the VP1 
capsid protein of EV-A71. Peptides SP55 (amino acids 
163-177 of VP1) and SP70 (amino acids 208-222 of VP1) 
could elicit neutralizing antibodies against EV-A71 in vitro. 
SP70 was identified as particularly potent in eliciting a 
neutralizing antibody titer compared to that obtained with 
whole virion-immune serum. The amino acid residues of 
epitope SP70 are more conserved than the VP1 sequences 
of various subgenogroups of EV-A71. However, obtaining 
superior synthetic antigens requires the use of more effective 
adjuvants. Although the yeast-expressed VP1 protein 
provides good immunogenicity, VP1 subunit vaccines 
require further refinement to contribute significantly to an 
effective vaccine strategy43.
Virus-like particle vaccine
Virus-like particles (VLPs) for EV-A71 are similar 
in morphology to the natural viral capsid structure and 
have been developed as potential vaccines46. Vaccination 
with an EV-A71 VLP vaccine showed significant potency 
against lethal challenge in newborn mice. However, an 
ideal enterovirus vaccine should be effective against both 
EV-A71 and Coxsackie virus-A16 (CV-A16) infections. 
Consequently, a bivalent enterovirus vaccine based on 
chimeric EV-A71 virus-like particles (ChiEV-A71 VLPs) 
has been proposed47. In chimeric EV-A71 VLPs, the 
neutralizing epitope SP70 within the capsid protein VP1 
of EV-A71 was replaced by CV-A16. Chimeric VLPs are 
able to elicit protective neutralizing antibodies against 
EV-A71 and CV-A16 in mice47. Although studies have 
demonstrated that VLP vaccines can induce protective 
neutralizing antibodies and show cross-protective efficacy 
against different EV-A71 subtypes not present in other 
experimental vaccines, these vaccines have a lower efficacy 
than inactivated vaccines. They must also be further studied.
DNA vaccines
DNA vaccines and recombinant vector DNA vaccines 
have been studied in EV-A71 vaccine development. Several 
research groups have designed and constructed a DNA 
vaccine against EV-A71 infection using its viral capsid 
protein (VP1) gene in order to verify the functionality of 
this vaccine in vitro and/or in vivo48-50. One study showed 
that vaccination with an EV-A71 DNA vaccine could 
elicit VP1-specific IgG titers and neutralizing antibodies 
against EV-A71, although it resulted only in low levels of 
antigenicity48. Another study by Chiu et al.49 investigated 
the potential use of attenuated Salmonella enterica serovar 
Typhimurium strains to express and deliver VP1 of EV-A71 
as a vaccine to prevent EV-A71 infections in mice. They 
showed that offspring born to female mice immunized 
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with Salmonella-based VP1 vaccine had higher survival 
rates (50-60%) than offspring of unvaccinated control 
mice (0%)49. Another study indicated that recombinant 
adenoviruses, expressing EV-A71 P1 and 3CD genes, could 
elicit production of neutralizing antibodies and protect against 
EV-A71 infection, both useful characteristics for the prevention 
of EV-A71 infections50. Although promising preliminar results 
have been shown, further investigation on the immunogenicity 
of this potential EV-A71 DNA vaccine is needed.
Live-attenuated virus vaccines
Cynomolgus monkeys inoculated with an attenuated 
EV-A71 vaccine showed mild neurological symptoms but 
survived lethal challenge by virulent EV-A71 (BrCr-TR) 
without exacerbation of symptoms51. Although this study 
indicated that the monkeys’ immunization with attenuated 
EV-A71 vaccine had the potential to produce significant 
titers of neutralized antibodies against different genogroups 
of EV-A71, including A, B1, B4, C2 and C451, several 
safety issues concerning live-attenuated virus vaccines 
need to be overcome. For example, immunization with the 
attenuated strain might cause mild neurological symptoms 
when inoculated via the intravenous route. However, a 
high-fidelity variant of EV-A71 exhibited an attenuated 
phenotype and showed an intriguing potential as a live-
attenuated EV-A71 vaccine52. 
Inactivated virus vaccines
Compared to the various vaccine candidates, inactivated 
EV-A71 vaccines are more capable of fulfilling the demand 
for prevention of EV-A71 infections. Inspired by previous 
developments of inactivated vaccines, the development 
of inactivated EV-A71 vaccines has progressed rapidly in 
recent decades. 
It has been demonstrated in mice that immunization 
with a formalin-inactivated EV-A71 vaccine can elicit high 
titers of EV-A71 virus-specific neutralizing antibodies, 
conferring protection against an EV-A71 lethal challenge53. 
After successful preclinical experiments, phase I and phase 
II clinical trials were performed to determine the efficacy 
of inactivated EV-A71 candidate vaccines. Immunization 
with inactivated EV-A71 vaccine elicited high titers of 
neutralizing antibody and induced specific T-cell reactions 
in the study population, with no significant inflammatory 
reaction reported54. In addition, another study indicated 
that inactivated EV-A71 vaccine candidates can elicit 
cross-neutralizing antibody responses against EV-A71 
subgenogroups B1, B4, B5 and C4A55. Due to their 
stability, the research and development of inactivated 
EV-A71 vaccines has progressed more rapidly compared 
to other types of vaccines. In recent years, at least five 
inactivated EV-A71 vaccine candidates have been developed 
and advanced to clinical trials. All EV-A71 vaccines 
developed in China are inactivated whole-virus alum-
adjuvant vaccines1. All of them use the C4 subgenogroup 
virus as the vaccine strain1. Randomized, double-blind, 
placebo-controlled trials of EV-A71 vaccines have been 
completed56. More than 30,000 infants and children have 
been involved in Phase III clinical trials of inactivated EV-
A71 C4 vaccines in China56. These studies have shown 
that the EV-A71 vaccines can prevent more than 90% of 
EV-A71-associated HFMD or herpangina and 80% of other 
EV-A71-associated disease symptoms. It has been reported 
that the seroconversion rate is 100% after two vaccinations, 
and all C4-based vaccines prevented EV-A71-associated 
hospitalizations. Furthermore, preexisting antibodies due 
to undetected subclinical infections in young children did 
not interfere with vaccine efficacy against different EV-A71 
genogroups57. However, the inactivated EV-A71 vaccines 
did not protect against CV-A161,57. 
Indurations, erythema, and pain at the injection site have 
been the most common side effects of EV-A71 vaccination; 
high fever has also occasionally been observed58. The rate 
of rare serious adverse events (SAEs) in vaccinated groups 
was not significantly different from that observed in control 
groups, and SAEs were not causally related to vaccination58. 
An estimation of the cost-effectiveness of a national 
EV-A71 vaccination has been performed in China59. It was 
shown that the vaccination would be cost-saving or cost-
effective due to prevention of EV-A71-related morbidity, 
mortality and use of health services among children aged 
five or younger, compared to anticipated costs with no 
vaccination. This finding bodes well for the introduction 
of a safe and effective EV-A71 vaccine in the near future. 
In December 2015, the Food and Drug Administration 
(FDA) of China approved an EV-A71-targeting vaccine59. In 
China, inactivated EV-A71 vaccines are now commercially 
available products. 
An inactivated EV-A71 vaccine still faces one major 
challenge60. Although both, C4-based and B4-based 
antibodies cross-neutralize the current circulating EV-A71 
isolates2, the B4 vaccine poorly neutralizes an atypical 
C2 strain. In addition, no formalin-inactivated EV-A71 
vaccines developed to date protect against CV-A16, which 
is a primary cause of annual HFMD outbreaks. Additionally, 
the humoral immunity associated with protection initially 
observed, appears to wane after the first 6 months of 
vaccination. However, inactivated EV-A71 vaccines have 
significant safety advantages over live-attenuated ones 
because of their inability to replicate. 
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CONCLUSIONS
EV-A71 is currently an important, threatening infectious 
agent in the world. It can cause severe neurological disorders 
and death in infected young children. Due to the lack of 
effective control measures, the development of effective 
vaccines is urgently needed for prevention and control of 
EV-A71 infections. Currently, several candidates for an 
EV-A71 vaccine exist, including a formalin-inactivated 
whole virus vaccine, DNA vaccines, VLP and recombinant 
protein vaccines. Monovalent EV-A71 vaccines are 
expected to be marketed soon in mainland China, if the 
process of production goes well. It has been estimated 
that EV-A71 vaccines will be effective and cost-saving in 
most developing countries59. Several promising inactivated 
EV-A71 vaccines have been developed in the last few 
years; however, they have certain limitations. Currently, 
inactivated EV-A71 vaccines can protect against EV-A71 
but not against CV-A16 infections. All of these EV-A71 
vaccines remain in the initial stages of development. 
Stability, purity and cost of production are the primary 
future challenges for these vaccines.
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